Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

/p>

Fourth quarter 2009 sales of $58.7 million were 9.9% lower than the fourth quarter 2008.  Excluding a 5.9% favorable impact of foreign exchange, reflecting a weaker U.S. dollar, sales decreased 15.8%.  The decrease is primarily due to lower volumes of an active pharmaceutical ingredient ("API") that utilizes the Company's polymeric drug delivery technology, lower sales of two APIs manufactured under long-term supply agreements and lower custom development revenues, all due to the timing of orders throughout 2009.  Volumes of a feed additive for which a contract expired earlier in 2009 were also lower.  Partially offsetting these decreases were increased generic revenues resulting from improved order patterns.

Fourth quarter 2009 Gross Margin increased to 24.7% of sales from 24.2% during the fourth quarter 2008, with foreign currency unfavorably impacting gross margin by 0.6% in the fourth quarter 2009.  Cost reductions, and to a lesser extent, positive product mix, were the main drivers of the higher margins.  This was partially offset by lower pricing of generic APIs and lower volumes of an API manufactured under a long-term supply agreement.

Selling, General and Administrative Expenses in the fourth quarter 2009 were $8.8 million compared to $9.0 million in the same period last year.  The decrease is a result of lower personnel costs and professional fees at the corporate headquarters and the benefit of the termination of certain postretirement benefits partially offset by higher legal fees, higher expenses at the Company's manufacturing sites and an unfavorable impact of foreign currency.

Research and Development Expenses increased to $2.0 million in the fourth quarter 2009 from $1.6 million in the fourth quarter 2008 due to high
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... NORTH BRUNSWICK, N.J. , May 28, 2015 ... that PDS0101, a cancer immunotherapy treatment targeting HPV-16, ... patients.  Currently, pre-cervical cancer is ... could offer a simple and effective non-surgical alternative. ... body,s defense mechanisms (T-cells) to recognize, target, and ...
(Date:5/28/2015)... May 28, 2015 The Fertility Centers ... own Dr. Danielle Vitiello has taken on a new ... Dr. Vitiello will provide guidance, leadership, oversight and quality ... count Dr. Vitiello among our team of experienced reproductive ... CEO, Joseph A. Hill, M.D. “Her expertise and compassionate, ...
(Date:5/28/2015)... Dr. Carl Peck, MD, Chairman ... L. Williams, MD, has joined the firm as ... are top tier consultants whose expertise and professional ... the company’s clients. Premier Experts collaborate to design ... develop their medical products, pursue optimal regulatory pathways, ...
(Date:5/27/2015)... DUBLIN , May 26, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Markets and Companies" to their offering. ... the molecular diagnostics technologies that will play ... public health, pharmaceutical industry, forensics and biological ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3
... , CARLISLE, Mass., Aug. 5 ... launch of a fully integrated microarray solution platform. ... biochips and advanced microarray instrument systems, in collaboration ... and instrumentation software, now offers a platform that ...
... , CHICAGO, Aug. 5 Advanced ... it will host a conference call and webcast discussing the Company,s ... a.m. (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, ... present an update on the Company. A press release reporting the ...
... Framework Reaffirmed , Shire plc (LSE: SHP, NASDAQ: SHPGY ) the global specialty,biopharmaceutical company, announces results for the ... ... Q2 2009(1), Product sales ... -21%, Product sales (excluding ADDERALL XR) $491 million ...
Cached Biology Technology:CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 2CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 3Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 3Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 4Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 5Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 6Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 7Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 8Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 9Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 10Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 11Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 12Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 13Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 14Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 15Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 16Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 17Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 18Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 19Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 20Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 21Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 22Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 23Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 24Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 25Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 26Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 27Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 28Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 29Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 30Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 31Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 32Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 33
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Ky. The University of Louisville today announced that ... into a license and research collaboration agreement with Novartis ... the potential to help transplant patients avoid taking anti-rejection ... for treatment of other diseases. The University ...
... Boston University School of Medicine (BUSM) suggests that epigenetics may ... relapse of cancer. The findings are published online in Volume ... The term epigenetics refers to the external modifications ... do not change the DNA sequence, but instead, they affect ...
... MA New insights into how human cytomegalovirus ... with infection spreads from pregnant mother to fetus ... translational researchers an exciting new avenue for investigation ... interventions. Using next generation sequencing and population genetic ...
Cached Biology News:University of Louisville researchers sign global licensing agreement 2University of Louisville researchers sign global licensing agreement 3BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy 2Research points to potential window for treating CMV and preventing mother-to-child transmission 2Research points to potential window for treating CMV and preventing mother-to-child transmission 3
... Designed to meet the ... this animal component-free medium supports ... high cell densities, while maintaining ... recombinant protein production using the ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z36,327-8) ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: